BeOne Medicines (SHSE:688235) EPS (Basic): ¥2.60 (TTM As of Mar. 2026)


SHSE:688235 BeOne Medicines Ltd SHSE:688235
70 GF Score
Price ¥236.79
GF Value ¥313.72
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BeOne Medicines EPS (Basic)?

BeOne Medicines SHSE:688235 +3.86% 70 EPS (Basic) is ¥2.60 as of Mar. 2026. GuruFocus rates SHSE:688235 with a GF Score™ of 70/100 and a GF Value™ of ¥313.72 (Modestly Undervalued). The stock has 4 warning signs investors should review.

BeOne Medicines's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was ¥1.10. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥2.60.

BeOne Medicines's EPS (Diluted) for the three months ended in Mar. 2026 was ¥1.03. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥2.32.

BeOne Medicines's EPS without NRI for the three months ended in Mar. 2026 was ¥1.72. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 5.43.

During the past 12 months, BeOne Medicines's average EPS without NRIGrowth Rate was 1825.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, BeOne Medicines's highest 3-Year average EPS without NRI Growth Rate was 27.00% per year. The lowest was -198.90% per year. And the median was -60.00% per year.

BeOne Medicines  (SHSE:688235) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

BeOne Medicines EPS (Basic) Related Terms

BeOne Medicines EPS (Basic) Historical Data

* Premium members only.

The historical data trend for BeOne Medicines's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines EPS (Basic) Chart

BeOne Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.71 -10.39 -4.64 -3.42 1.41

BeOne Medicines Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.50 0.64 0.35 1.10
SHSE:688235
70GF Score
BeOne Medicines Ltd SHSE:688235
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BeOne Medicines EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

BeOne Medicines's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(2020.927-0)/1417.804
=1.43

BeOne Medicines's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(1566.967-0)/1442.452
=1.09

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of ¥2.60 mean?
BeOne Medicines (SHSE:688235) has a EPS (Basic) of ¥2.60 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on BeOne Medicines and its competitors.
Is BeOne Medicines' EPS (Basic) too high?
BeOne Medicines' current EPS (Basic) is ¥2.60. Overall, BeOne Medicines has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' EPS (Basic) compare to RVMD and RPRX?
BeOne Medicines' EPS (Basic) of ¥2.60 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current EPS (Basic) is ¥2.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (SHSE:688235) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥313.72, compared to a current price of ¥236.79 — trading 24.5% below its estimated fair value. The current EPS (Basic) is ¥2.60. BeOne Medicines' overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For BeOne Medicines (SHSE:688235), the current EPS (Basic) is ¥2.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (SHSE:688235) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of ¥236.79 is trading 24.5% below its estimated GF Value™ of ¥313.72. GuruFocus considers BeOne Medicines to be Modestly Undervalued.

Key valuation signals for SHSE:688235:

  • EPS (Basic): ¥2.60
  • GF Value™: ¥313.72 vs. price of ¥236.79 (24.5% below fair value)
  • GF Score™: 70/100 with 4 warning signs

No single metric tells the full story. See the SHSE:688235 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
70GF Score

Get the complete analysis for SHSE:688235

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥236.79
Price
¥313.72
GF Value